Last reviewed · How we verify
Amidrine (OCTODRINE)
Amidrine (generic name: OCTODRINE) is a octodrine drug. It is currently in Phase 2 development.
Amidrine is believed to work by stimulating the central nervous system.
Amidrine, also known as Octodrine, is a small molecule drug of the octodrine class. Its exact target and mechanism of action are unknown, but it is believed to work by stimulating the central nervous system. Amidrine is not FDA-approved for any indications, and its commercial status is unclear. As a result, there is limited information available on its safety profile and pharmacokinetic properties. Further research is needed to fully understand the potential benefits and risks of this compound.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | OCTODRINE |
|---|---|
| Drug class | octodrine |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain as a computer - Amidrine is thought to be like a software update that helps increase alertness and focus by enhancing the communication between different parts of the brain. This can lead to improved mental clarity and a sense of energy, but more research is needed to confirm its effects and potential side effects.
Approved indications
Common side effects
Key clinical trials
- A Randomized, Open-label, Multiple Dose, Two-part Phase I Clinical Trial to Compare the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of DWP14012 After Administrations of DWP14012 Alone a (Phase 1)
- Primary vs. Secondary Closure of Cutaneous Abscesses After I&D: A RCT (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amidrine CI brief — competitive landscape report
- Amidrine updates RSS · CI watch RSS
Frequently asked questions about Amidrine
What is Amidrine?
How does Amidrine work?
What is the generic name of Amidrine?
What drug class is Amidrine in?
What development phase is Amidrine in?
Related
- Drug class: All octodrine drugs
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing